Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential

3. Repligen Corp (NASDAQ:RGEN)

Maverick Capital Equity Stake: $178.95 Million

Number of Hedge Fund Holders: 40

Stock Upside Potential: 41.26%

Repligen Corp (NASDAQ:RGEN) is one of billionaire Lee Ainslie’s stocks with huge upside potential. Analysts see Repligen stock soaring more than 40% from its current level.

On May 15, RBC Capital resumed coverage on Repligen Corp (NASDAQ:RGEN) stock with an Outperform rating and a price target of $160. The firm cited the company’s growth potential, noting the diversity of Repligen’s growth drivers and the strengthening bioprocess market.

According to the firm, these factors should enable Repligen to return to mid-teens organic sales growth. Additionally, RBC Capital cited several tailwinds, including commercial mix and biosimilars.

Repligen’s Q1 2026 results showed a strong start to the year. Revenue increased 15% YoY to $194 million and exceeded analysts’ forecast of $192.1 million. Adjusted EPS rose to $0.48 from $0.39 a year ago and beat the consensus estimate of $0.38.

Looking ahead, Repligen reaffirmed its full-year 2026 revenue and adjusted EPS guidance. It anticipated full-year revenue in the range of $803 million to $833 million, reflecting a growth of 9% to 13%. It expects adjusted EPS in the band of $1.97 to $2.05. Repligen CEO Olivier Loeillot said their focus right now is on accelerating profitable growth.

Repligen Corp (NASDAQ:RGEN) is a bioprocessing company. It develops and manufactures products used by pharmaceutical companies to produce biological drugs. Repligen’s products and technologies are designed to make biological drug manufacturing more efficient and cost-effective.

1281292 - 11759070 - 1